Get the Stockscreener App
8.40
0.36%
-0.03
After Hours:
8.40
Novavax Inc stock is traded at $8.40, with a volume of 3.50M.
It is down -0.36% in the last 24 hours and down -3.11% over the past month.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
See More
Previous Close:
$8.43
Open:
$8.33
24h Volume:
3.50M
Relative Volume:
0.59
Market Cap:
$1.36B
Revenue:
$1.08B
Net Income/Loss:
$422.82M
P/E Ratio:
3.6842
EPS:
2.28
Net Cash Flow:
$-637.33M
1W Performance:
-1.41%
1M Performance:
-3.11%
6M Performance:
+25.94%
1Y Performance:
-12.59%
1-Day Range:
$8.27
$8.535
1-Week Range:
$8.25
$8.7535
52-Week Range:
$5.01
$11.55
Novavax Inc Stock (NVAX) Company Profile
Name
Novavax Inc
Sector
Industry
Phone
240-268-2000
Address
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Compare NVAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
8.40 | 1.37B | 1.08B | 422.82M | -637.33M | 2.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-25 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-28-25 | Resumed | H.C. Wainwright | Buy |
| Aug-20-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-17-25 | Initiated | Citigroup | Sell |
| Feb-28-25 | Initiated | BTIG Research | Buy |
| Jul-30-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-10-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-10-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-09-23 | Reiterated | B. Riley Securities | Buy |
| Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-02-22 | Initiated | Jefferies | Hold |
| Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Feb-22-22 | Resumed | Jefferies | Buy |
| Jan-21-22 | Initiated | Cowen | Outperform |
| May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-29-20 | Reiterated | B. Riley FBR | Buy |
| Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
| May-28-20 | Reiterated | B. Riley FBR | Buy |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
| Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
| Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax Inc Stock (NVAX) Latest News
Signal strength of Novavax Inc. stock in tech scannersLayoff News & Free Long-Term Investment Growth Plans - newser.com
Market reaction to Novavax Inc.’s recent newsLong Setup & Risk Adjusted Swing Trade Ideas - newser.com
Key metrics from Novavax Inc.’s quarterly dataCEO Change & Entry Point Strategy Guides - newser.com
Will breakout in Novavax Inc. lead to full recoveryPortfolio Risk Report & Safe Entry Trade Signal Reports - newser.com
Why Novavax Inc. stock could rally in 2025Chart Signals & Real-Time Chart Pattern Alerts - newser.com
What moving averages say about Novavax Inc.2025 Volume Leaders & Verified Entry Point Signals - newser.com
How interest rate cuts could boost Novavax Inc. stockJuly 2025 Drop Watch & Daily Market Momentum Tracking - newser.com
How Novavax Inc. stock compares to market leaders2025 Valuation Update & Safe Capital Growth Stock Tips - newser.com
Novavax (NVAX) to Release Earnings on Thursday - MarketBeat
B. Riley Issues Pessimistic Outlook for Novavax Earnings - MarketBeat
How Novavax Inc. (NVV1) stock moves on employment data2025 Earnings Surprises & Stepwise Trade Signal Implementation - newser.com
Why Novavax Inc. stock remains on watchlistsGold Moves & High Yield Equity Trading Tips - newser.com
Can Novavax Inc. stock reach $100 price targetJuly 2025 Closing Moves & High Yield Stock Recommendations - newser.com
Can Novavax Inc. stock sustain market leadershipPortfolio Return Report & AI Powered Trade Plan Recommendations - newser.com
Will Novavax Inc. (NVV1) stock benefit from sector leadershipJuly 2025 Trade Ideas & Daily Stock Momentum Reports - newser.com
Published on: 2025-10-31 05:03:55 - newser.com
Published on: 2025-10-31 04:02:31 - newser.com
Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025 - Yahoo Finance
The Math Shows PRF Can Go To $51 - Nasdaq
Published on: 2025-10-30 02:32:13 - newser.com
Novavax (NVAX) Gains Momentum with Sanofi Deal and Analyst Endorsement - Insider Monkey
Novavax Inc NVV1 Stock Analysis and ForecastVolatility Adjusted Trading & Access Free Tools and Start Investing - earlytimes.in
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why - sharewise.com
Novavax Inc Stock (NVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):